Unmet need in chronic hepatitis B management
Despite all these exciting developments, there remain some unmet needs in the management for patients with chronic hepatitis B (CHB). As majority of CHB patients are going to use oral nucleos(t)ide analogues (NAs) for decades, Safety profile of NAs is of no doubt an important issue. The newest nucle...
Main Authors: | Lilian Yan Liang, Grace Lai-Hung Wong |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of the Liver
2019-03-01
|
Series: | Clinical and Molecular Hepatology |
Subjects: | |
Online Access: | http://e-cmh.org/upload/pdf/cmh-2018-0106.pdf |
Similar Items
-
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
by: Hung-Yao Lin, et al.
Published: (2022-04-01) -
Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
by: Pei-Yuan Su, et al.
Published: (2021-11-01) -
Cost–effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
by: Emmanouil Sinakos, et al.
Published: (2024-02-01) -
Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B
by: Tomohiro Nishikawa, et al.
Published: (2024-02-01) -
Evaluation Effect of Tenofovir Alafenamide (TAF) in Long-Term Therapy for Chronic Hepatitis B: A Systematic Review
by: Rada Citra Saputra, et al.
Published: (2022-12-01)